🇺🇸

US SEC Filing Intelligence

· daily

Big Pharma Approvals — March 04, 2026

This period yields four neutral signals from Big Pharma approvals, with only Janssen's PREZCOBIX (darunavir/cobicistat) providing substantive details on a standard-review original NDA approved 2026-02-27. Three identical, empty records for Novo Nordisk's SOMAPACITAN-BECO represent 75% concentration but offer zero insights, signaling potential data gaps. No bullish/bearish catalysts emerge; monitor for label clarity to assess portfolio impact.

4 total filings
· daily

Orphan Drug Approvals — March 04, 2026

Two Priority Review orphan drug approvals on 2026-02-27 deliver bullish catalysts for Ascendis Pharma and BioMarin Pharm, with NME status for Ascendis' NAVEPEGRITIDE and efficacy supplement for BioMarin's PEGVALIASE-PQPZ. Orphan designations across both enable 7-year market exclusivity and premium pricing in rare disease markets. Unspecified indications cap addressable market visibility, warranting caution on revenue potential.

2 total filings
· daily

New Drug Approvals (Original) — March 04, 2026

This one-day snapshot reveals 7 FDA approvals dominated by 4 routine ANDA generics (Apotex, Macleods, Humanwell, Anthea) with neutral implications due to pricing pressures and unspecified markets. A single high-impact bullish signal emerges from Ascendis Pharma's NME-priority-orphan approval for NAVEPEGRITIDE (YUVIWEL), signaling premium pricing potential and biotech upside. Overall neutral period for institutional portfolios, with limited sector visibility absent therapeutic details.

7 total filings
· daily

DHS Homeland Security Contracts — March 04, 2026

DHS awarded $2.29B in contracts dominated by a $2.08B Coast Guard FRC shipbuilding obligation to Bollinger Shipyards, signaling multi-year commitment to complete a 58-cutter fleet by 2028. Smaller $105M and $105M awards to Birdon and BCCG highlight long-term ship repair (to 2034) and near-term border barrier construction. Bullish for shipbuilding sector (NAICS 336611) with 96% of value, amid low initial outlays across all.

3 total filings
· daily

Federal Construction & Infrastructure Contracts — March 04, 2026

Two major federal construction contracts totaling $511.2M under NAICS 236220 signal strong demand for institutional buildings, with Brasfield & Gorrie LLC showing $383M progressed execution on a $407M DOJ/FBI project and BCCG JV securing a fully obligated $104.7M DHS/CBP border barrier award. Both firm-fixed-price delivery orders, awarded via full/open competition to non-small businesses, highlight momentum in secure federal infrastructure through 2026. Investors should prioritize these contractors for revenue visibility while monitoring cost overrun risks.

2 total filings
· daily

New Federal Contractors — March 04, 2026

This one-day snapshot reveals $3.84B in new federal contract records, with 54% ($2.08B) concentrated in DHS Coast Guard shipbuilding awards to Bollinger Shipyards, signaling multi-year maritime fleet expansion to 58 FRCs. Six bullish signals dominate across shipbuilding, construction, and IT services, driven by full/open competition wins, while HHS scientific services remain neutral. Investors should prioritize DHS-exposed defense industrials and monitor low initial outlays ($0-$10M on three contracts >$100M) for execution risks.

7 total filings
· daily

Significant Contract Modifications ($10M+) — March 04, 2026

DHS dominates with $2.3B+ in shipbuilding and border infrastructure mods, signaling sustained homeland security spending through 2034. Six bullish signals across $3.8B total value highlight revenue stability for contractors in shipbuilding, construction, and federal IT/health services. Neutral ATCC contract underscores nonprofit stability in CDC funding, but fixed-price risks warrant caution in construction-heavy awards.

7 total filings
· daily

Contract Deobligations Alert — March 04, 2026

DHS dominates with $2.3B+ in multi-year shipbuilding and border construction contracts, signaling sustained homeland security spending through 2034. Six bullish signals highlight revenue visibility for prime contractors amid low initial outlays, positioning defense and construction firms for growth. Neutral HHS nonprofit award underscores stable but non-equity scientific funding, with total obligations at $3.84B indicating robust federal commitments.

7 total filings
· daily

Contract Option Exercises — March 04, 2026

DHS commands 60%+ of $3.84B total obligations via massive shipbuilding (Bollinger $2.08B, Birdon $106M) and border construction (BCCG $105M) awards, signaling multi-year homeland security capex acceleration through 2034. Six bullish signals dominate across defense manufacturing, construction, and IT/services, with unexercised options adding $500M+ upside potential. Neutral nonprofit HHS award provides minor offset but underscores steady scientific funding amid fixed-price execution risks.

7 total filings
· daily

All HHS Contracts — March 04, 2026

HHS deployed $337M in stable funding for CDC reagent supply and CMS Medicare appeals processing, affirming long-term commitment to public health infrastructure through 2026-2029. Bullish for for-profit Maximus with $104M firm-fixed revenue and $17.5M runway; neutral for nonprofit ATCC's $233M cost-plus contract with $257M options upside. Cross-pattern: full/open competition favors established vendors in scientific/admin services, signaling sector resilience amid federal budget continuity.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — March 04, 2026

DHS dominates with $2.28B in mega-contracts for shipbuilding (Bollinger $2.08B, Birdon $106M) and border barriers (BCCG $105M), signaling sustained homeland security capex through 2034. Six bullish signals highlight construction and IT/services momentum, with $3.84B total obligations and $1.0B+ in unexercised options for upside. HHS awards ($337M) provide steady health services funding to 2029, though neutral equity impact from nonprofit recipient.

7 total filings
· daily

High-Value Federal Grants ($5M+) — March 04, 2026

High-value federal contracts totaling $3.84B over this one-day period underscore DHS dominance with $2.29B in shipbuilding and border security awards to Bollinger ($2.08B), Birdon ($106M), and BCCG ($105M), providing multi-year revenue (up to 2034). Bullish signals prevail (6/7) across defense, IT, construction, and health services, with SAIC ($806M), Brasfield ($407M), and Maximus ($104M) highlighting steady execution ($377M-$383M outlayed). Neutral ATCC ($233M) nonprofit award tempers health sector upside, but unexercised options across portfolio (~$500M+ potential) signal growth amid fixed-price execution risks.

7 total filings
· daily

General Federal Contracts — March 04, 2026

DHS dominates with $2.29B (60%) in contracts for Coast Guard shipbuilding and border barriers, signaling multi-year commitments to maritime and border security amid fleet expansion to 58 FRCs and long-term vessel programs. HHS and other agencies add $0.67B in health/IT services and construction, with 6/7 bullish signals driven by high obligations ($3.84B total) and unexercised options up to $0.7B+. Investors should prioritize DHS-exposed shipbuilders and constructors for revenue visibility through 2034, monitoring fixed-price execution risks.

7 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 04, 2026

Across 50 filings from the USA S&P 500 Consumer Staples intelligence stream (broadly including food, beverages, household, and adjacent sectors), overarching themes include heightened governance activity with 12+ proxy statements (DEF 14A/DEFA14A) signaling board refreshes, annual meetings, and shareholder proposals, alongside mixed financial results showing revenue growth in 6/20 reporting companies (avg +30% YoY outliers like Kontoor +21%, Bankwell +25% total revenue) but declines in 7/20 (avg -8% YoY, e.g., Cracker Barrel -7.9%). Margin trends are bifurcated: expansions in 5 companies (ImmuCell +1140bps to 41.4%, Pulmonx Q4 +400bps to 78%) versus compressions in 4 (Kontoor op margin -240bps to 10.7%). Capital allocation leans defensive with steady dividends (Horizon $0.06/month, Helmerich $0.25/quarter) and buybacks (Kontoor repurchased at $67.58 avg), while divestitures (Hain Celestial Snacks sale) and M&A progress (Horizon-Monroe merger) aim to deleverage. Forward-looking catalysts cluster in Q2 2026 (10+ AGMs April-May) and biotech milestones (Cellectar EMA Q3 2026), but cash burns (Cellectar -43% YoY) and net losses (12/25 firms) flag funding risks. Portfolio-level, neutral-mixed sentiment (60% mixed/neutral) implies sector resilience amid consumer pressures, favoring dividend payers and turnaround plays.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 04, 2026

Across 69 SEC filings from S&P 500 Industrials and related sectors, dominant themes include mixed financial results with revenue growth in 12/20 key earners (avg +15% YoY, e.g., Black Rock Coffee +24.5%, CPS Technologies +54%) offset by widespread margin compression (avg -150 bps in 8/15 reporters) and net loss expansions (e.g., Ocugen +25%, Rigetti +8%). Biotech and tech firms highlight clinical catalysts (e.g., Ocugen OCU410ST interim Q3 2026, EyePoint DURAVYU topline mid-2026) amid cash burn concerns, while industrials like Babcock & Wilcox show backlog surges (+470% YoY). SPAC activity intensifies with extensions (Goldenstone to Dec 2026) and mergers (Bleichroeder-Pasqal $2B valuation), signaling M&A momentum. Capital allocation leans toward buybacks/dividends (Abercrombie $450M repurchase, Bath & Body $400M) but dilutions via equity raises dilute shareholders (Regen BioPharma +77M shares). Portfolio-level trends flag deteriorating profitability despite top-line resilience, with forward guidance cautious (e.g., Cracker Barrel revenue -2.5-4.5% FY2026). Actionable implications: Favor backlog-rich industrials, monitor biotech catalysts, avoid high-dilution names.

34 high priority 35 medium 69 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 04, 2026

Across the four filings in the S&P 500 Energy stream, Hess Midstream LP dominates with positive capital allocation via a $60M accretive repurchase program, signaling strong management conviction and commitment to 5% annual distribution growth through 2028 while preserving $1B in flexibility. Real Brokerage Inc. highlights a pristine balance sheet with zero long-term debt, leases, or liabilities, and 210.5M shares outstanding, underscoring financial stability amid no ICFR changes. BRT Apartments Corp. reports a smooth CFO transition with vesting of 42,800 restricted shares but forfeiture of RSUs, maintaining neutral sentiment. A Paradise Acquisition Corp.'s SPAC pursuit of Enhanced Ltd. reveals mixed sentiment due to high risks like regulatory scrutiny and minimal revenue, contrasting sector peers. No uniform period-over-period trends emerge as filings lack comprehensive financial comparisons, but capital returns and low-debt profiles point to defensive positioning. Key implication: Energy midstream shows shareholder-friendly actions amid limited sector catalysts on March 4, 2026.

3 high priority 1 medium 4 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 04, 2026

Across 365 SEC filings from diverse S&P 500 Financials-adjacent sectors (including banks, insurers, healthcare, energy, retail), overarching themes include robust YoY revenue growth averaging +15% in high-materiality filings (e.g., National Vision +9% FY, Viemed +21% FY, BillionToOne +100% FY), but widespread margin compression (-100 to -200 bps YoY in 12/20 key reports like Gran Tierra -37% netback, Grocery Outlet impairments) and mixed profitability with 40% reporting net losses or widened deficits. Capital allocation trends favor shareholder returns (buybacks in 15 filings totaling $500M+, dividends steady/growing in 10 like Horizon $0.18/share Q2), while M&A/refinancings (e.g., Cooper-Standard debt swap, SSR Mining $1.5B asset sale) signal deleveraging. Insider activity sparse but positive conviction in repurchases; forward guidance optimistic for 2026 (revenue +10-40% in 20 filings). Portfolio-level: Healthcare/biotech shows pipeline catalysts (Ocugen Phase 3 topline Q1 2027) offsetting cash burn; energy mixed on production vs. prices; retail impairments flag caution. Actionable: Favor growth names with raised guidance amid macro volatility.

193 high priority 172 medium 365 total filings